Key result
Comprehensive management with metreleptin improves metabolic control in congenital generalized lipodystrophy.
Why the study?
Congenital generalized lipodystrophy is a rare disease with limited long-term clinical data on management and outcomes, especially in patients with BSCL2 mutations.
Case Report (n=2)
Supports comprehensive metreleptin management in congenital generalized lipodystrophy; hypothesis-generating pending larger prospective studies.
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disease that is characterized by loss of subcutaneous and visceral adipose tissues, and associated with dysregulation of glycolipid metabolism. In the present study, we reported the clinical manifestations and treatments of Japanese siblings with CGL caused by BSCL2 gene mutations with a clinical course of approximately 20 yr. Comprehensive management with metreleptin therapy, dietary control with additional medication, and psychosocial counseling in line with the patients’ stages of growth and development were important in achieving long-term metabolic control of this condition.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2019) conducted a case report in Congenital generalized lipodystrophy (Berardinelli-Seip syndrome) (n=2). Metreleptin was evaluated. Comprehensive management including metreleptin therapy, dietary control, and psychosocial counseling successfully controlled lipid and carbohydrate metabolism in two siblings with congenital generalized lipodystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: